Dr. Evans provides considerations in applying for a K99 Award. Provided by the UCLA Clinical and Translational Science Institute. More information at https://ctsi.ucla.edu/education/pages/edtools and https://ctsi.ucla.edu/education/pages/kprogram Presenter: Christopher Evans, PhD Professor of Psychiatry and Biobehavioral Sciences at UCLA Director, Brain Research Institute

1. K99/R00 - Awards
“Pathway to Independence”
Chris Evans
310 206 7884
cevans@ucla.edu
1-2 years of
Mentored
Research
3 years of
Independent
Research
+

2. PURPOSE:
K99 - To support the initial phase of a Career/Research Transition award
program that provides 1-2 years of mentored support for highly motivated,
advanced (but not too advanced) postdoctoral research scientists.
R00 - To support the second phase of a Career/Research Transition award
program that provides 1 -3 years of independent research support (R00)
contingent on securing an independent research position. Award recipients will
be expected to compete successfully for independent R01 support from the NIH
during the R00 research transition award period.
Bottom Line
2 years mentored research – move to faculty slot – 3 years R01-like funding
Only apply if mentor totally onboard – he/she has a lot of work to do!
Questions and Answers
https://grants.nih.gov/grants/new_investigators/QsandAs.htm
Peruse CTSI resources and a couple that have worked!
https://ctsi.ucla.edu/funding/pages/grant-writing
https://www.ctsi.ucla.edu/funding/pages/

3. REQUIREMENTS/ELIGIBILITY:
 K99 will support non-US citizens but must be in the US for training and R00.
 Must be at the time of application submission (or resubmission) in postdoctoral
training.
 Must have a terminal clinical or research doctorate (including Ph.D., M.D., D. O.,
D.C., N.D., D.D.S., D.V.M., Sc.D., D.N.S., Pharm. D.,) or equivalent doctoral
degree, or a combined degree.
 no more than 4 years of postdoctoral research experience since completing the
requirements of the doctoral degree (resubmissions must also comply with this
requirement). Note: this time can be extended due pregnancy, parenting,
military service and other personal issues reducing ability to work.

4. https://report.nih.gov/success_rates/
Success Rate Varies Enormously by Institute!!
NLM, NIAMS, NIAD < 15%
NIAAA, NINR, NIMHD > 50%

5. UCLA K99 (funded/applied)
NATIONAL DATA 2012 (%)
NCI = 1 / 7 apps 25.4%
NEI = 0 / 1 app 14.3%
NHLBI = 7 /18 apps 22.3%
NIA = 0 / 6 apps 35.5%
NIAAA = 0 / 4 apps 38.9%
NIAMS = 0 / 4 apps 14.3%
NIBIB = 0 / 1 app 15.2%
NICHD = 0 / 7 apps 16.4%
NIDA = 2 / 3 apps 50.0%
NIDCR = 2 / 7 apps 21.4%
NIDDK = 0 / 2 apps 18.5%
NIGMS = 0 / 6 apps 11.0%
NIMH = 3 / 12 apps 22.6%
NIHMD = 0 / 1 app ?
NINDS = 1 / 12 apps 17.6%
NINR = 0 / 1 app 60%
In order of ranking of Institute
funding to UCLA
Total Budget 2017
UCLA
2017
Rank
NIMH (Mental Health) $1,367,948,107 $39,300,711 4 (#3 in 2018)
NCATS (Translational) $578,421,698 18,129,593 6 (#6 in 2018)
FIC (Fogarty) $71,382,502 $1,936,190 7
NEI (Eye) $575,466,651 $10,779,819 8 (#14 in 2018)
NIDCR (Dental) $311,102,635 $8,213,872 8 (#9 in 2018)
NICHD (Child) $1,079,044,282 $20,222,500 8 (#9 in 2018)
NIGMS (General Med) $2,544,710,433 $37,890,352 9 (#15 2018)
NIDA (Drug) $935,420,689 $15,160,844 10 (#8 in 2018)
NLM (Library) $77,694,543 $1,892,208 11
NINR (Nursing) $77,694,543 $2,761,947 12 (#14 in 2018)
NIAMS (Arthritis) $465,165,152 $9,023,948 12
NCI (Cancer) $3,849,133,346 $58,713,575 12 (#12 in 2018)
NINDS (Stroke) $1,526,569,359 $23,990,468 14 (#11 in 2018)
NIBIB (Biomed/engineering) $348,391,567 $4,982,308 15
NIEHS (Environmental) $502,337,470 $7,010,882 20
NHGRI (Genome) $446,918,163 $6,027,644 21 (33 in 2018)
NIA (Aging) $1,735,568,749 $23,259,472 21 (23 in 2018)
OD (Office Director) $687,036,612 $8,450,198 21
NHBLI (Lung/Blood) $2,683,725,622 $36,478,011 22 (21 in 2018)
NIDCD (Deafness) $351,191,578 $4,388,558 22
NIAID (Allergy) $3,692,745,723 $39,008,979 25 (25 in 2018)
NIAAA (Alcohol) $355,497,576 $3,777,992 27 (31 in 2018)
NIDDK (Diabetes) $1,697,207,499 $16,804,091 32 (32 in 2018)
NCCAM/NCCIH Integrative $112,218,767 $935,771 36
NIMHD (Disparities) $245,071,212 $2,008,367 44 (40 in 2018)
Is there UCLA
reputation bias?
Is there a PI
reputation bias?
Other biases?

6. Racial Disparities during 2007-2017 in
K99/R00 Awards and Conversions to R00
Potential reasons:
• Preparation/opportunities
• Mentors implicit/explicit biases
• Stereotype Threat
• Reviewer implicit/explicit biases
http://rescuingbiomedicalresearch.org/blog/examining-distribution-k99r00-awards-race/
http://datahound.scientopia.org/2014/07/21/k99-r00-evaluation-a-striking-gender-disparity/

7. What Reviewers Will Look For?
1) Good track record – high impact publications –and publications that have
primary authorship. Explain contributions to “team science” multi-author
publications. Highlight success in different environments.
2) Preliminary data –innovation, potential impact, rigor of the research project to
the NIH institute you are applying to. Remember this is a training grant and
needs to demonstrate good rationale for acquiring new techniques and
methodologies, and creating a base for accomplishing the desired project and
transitioning to the ROO phase. Avoid acronyms and explain the importance of
the problem and your hypothesis rigorously – get reviewers excited.
3) The training plan – which can be more/just as important than the research ideas.
This is a place in which reviewers can get very picky, especially if they are not
swayed by the science. Staying in one location and area of research for all
training is considered a negative – learning complementary approaches good.
4) Good reference letters from well-established and high-impact researchers in the
field. Don’t go to your friends down the hall – cultivate letters from faculty that
are relevant in your area and ask your mentor to help out here.
5) Mentor/training environment is critical. Positives are NIH grants for mentor,
training track record (use co-mentor if any weaknesses), institutional
opportunities, different from Ph.D. mentor/environment.

8. THE NIH CV
Snapshot of who
you are, what you
are good at, what
you have done,
what you want to
do and where you
want to be.
Big deal for 1st
impression that
usually stays with
reviewers!

9. In C allowed 5 contribution Categories max 4 publications/category.
I would advise
using as many
contribution
categories as you
can and explain
your role on each
paper, especially
if not first author.

10. Critical to include
Complete Biography
Upload to either:
MyBibliography or
SciENcv.
Use reverse
chronological –
most recent first.

11. Make yourself known to a PO and ask advice in the institute you are applying to!
https://researchtraining.nih.gov/programs/career-development/K99-R00
NIH Funding Opportunity Announcements
The links below provide details on participating Institutes, funding amounts, period of performance,
application dates and eligibility:
NIH Pathway to Independence Award
(Parent K99/​R00 - Clinical Trial Required)
https://grants.nih.gov/grants/guide/pa-files/PA-18-397.html
National Cancer Institute (NCI)
National Eye Institute (NEI)
National Heart, Lung, and Blood Institute (NHLBI)
National Human Genome Research Institute (NHGRI)
National Institute on Aging (NIA)
National Institute on Alcohol Abuse and Alcoholism (NIAAA)
National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
National Institute of Biomedical Imaging and Bioengineering (NIBIB)
National Institute of Child Health and Human Development (NICHD)
National Institute on Deafness and Other Communication Disorders (NIDCD)
National Institute of Dental and Craniofacial Research (NIDCR)
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
National Institute on Drug Abuse (NIDA)
National Institute of Mental Health (NIMH)
National Institute of Neurological Disorders and Stroke (NINDS)
National Institute of Nursing Research (NINR)
National Institute on Minority Health and Health Disparities (NIMHD)
National Center for Complementary and Integrative Health (NCCIH)
National Institute of Environmental Health Sciences (NIEHS)
NIH Pathway to Independence Award (Parent K99/​R00
Independent Clinical Trial Not Allowed)
https://grants.nih.gov/grants/guide/pa-files/PA-18-398.html
National Cancer Institute (NCI)
National Eye Institute (NEI)
National Heart, Lung, and Blood Institute (NHLBI)
National Human Genome Research Institute (NHGRI)
National Institute on Aging (NIA)
National Institute on Alcohol Abuse and Alcoholism (NIAAA)
National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
National Institute of Allergy and Infectious Diseases (NIAID)
National Institute of Biomedical Imaging and Bioengineering (NIBIB)
National Institute of Child Health and Human Development (NICHD)
National Institute on Deafness and Other Communication Disorders (NIDCD)
National Institute of Dental and Craniofacial Research (NIDCR)
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
National Institute on Drug Abuse (NIDA)
National Institute of Environmental Health Sciences (NIEHS)
National Institute of General Medical Sciences (NIGMS)
National Institute of Mental Health (NIMH)
National Institute of Nursing Research (NINR)
National Institute on Minority Health and Health Disparities (NIMHD)
National Library of Medicine (NLM)
National Center for Complementary and Integrative Health (NCCIH)
National Institute of Neurological Disorders and Stroke (NINDS)

12. Thanks to Sarah Klein from the Semel:
1. DETERMINE IF YOUR STUDY MEETS THE NIH DEFINITION OF A CLINICAL TRIAL
(get help from your mentor)
a) Review case studies, FAQ’s for CT definition (https://grants.nih.gov/policy/clinical-
trials/definition.htm ). Contact PO ASAP if unsure
b) Helpful overview by NIH Deputy Director, Mike Lauer;
https://nexus.od.nih.gov/all/2018/01/04/further-refining-case-studies-and-faqs-about-the-
nih-definition-of-a-clinical-trial-in-response-to-your-questions/
2. SELECT APPROPRIATE FUNDING OPPORTUNITY (FOA)
a) Identify a FOA with the appropriate CT indicator for the project you propose
•'Independent Clinical Trial Required'(does not allow CT research experience!)
•'Independent Clinical Trial Not Allowed'(allows CT research experience!)
3.If your study meets the CT definition
DETERMINE IF YOU ARE PROPOSING AN INDEPENDENT CLINICAL TRIAL
a) Independent clinical trial: Applicant proposes to serve as the lead investigator of a
clinical trial, as part of their research and career development (mostly budgetary).
b) CT research experience lead by someone else (not independent): Applicant involved in a
clinical trial led by another investigator which provides experience relevant to their research
project and/or career development goals. NIH expects the mentor or individual receiving
support for the larger trial to assume overall responsibility for the trial. Important for:
• Which funding opportunity announcement you can respond to
• What information you need to include in the application
• What your responsibilities are with regards to the trial once you receive a grant award

13. 4. FAMILIARIZE YOURSELF WITH THE MOST CURRENT NIH APPLICATION GUIDE AND FOA?
Review the current NIH application guide (FORMS-E) filtered view for CDA applications in
conjunction with the correct FOA (pay close attention to FOA review criteria!)
Do not rely on a previously funded application as your guide(the instructions have changed)
5. DO THE RIGHT PEOPLE KNOW ABOUT YOUR PROPOSAL AND KNOW WHAT TO PROVIDE?
Request early!!!!
Mentors / Co-Mentors(for mentored CDAs): Mentors must provide 1) Mentoring Plan, 2)
Biosketch, 3) Other Support 4) Current eRA Commons login ID Synergy with application
Collaborators/Consultants: LOS and or biosketch if considered “key personnel”
Referees (for mentored CDAs):Reference letters from 3 individuals other than your mentor or
collaborators by the due date. Letters are managed through the eRA Commons system.
Department Chair: Your application requires a 1-page “Institutional Commitment Letter” on
official letterhead as part of your training plan. Must meet NIH guide requirements.
Department Academic Personnel: Before starting your application, discuss proposed UCLA
professional trajectory with mentor, including appropriate appointment series / titles
/salaries.
You (PD/PI):In addition to the proposal, make sure that your eRA commons login has PD/PI
role and is affiliated with UCLA.

14. 6. IS SOMEONE HELPING YOU WITH THE ADMINISTRATIVE ASPECTS?
a) An administrator within your Department/Center/Division may be available to limited
proposal coordination; discuss with mentor if support is available.
b) If yes, meet with your administrator ASAP to review FOA and NIH Application Instructions
c) Delegate responsibilities and generate a timeline
7. DO YOU KNOW HOW AND WHEN YOUR APPLICATION WILL BE SUBMITTED TO NIH?
UCLA uses a System to System Program called “Cayuse” a web-based alternative for preparing,
validating, and submitting proposals via Grants.gov. Request Cayuse access from
departmental administration.
Once the proposal is uploaded into Cayuse, it will be reviewed and submitted by a UCLA
Institutional Official. Most K-applications are submitted by a department official and require at
least 5-business days for pre-review
8.THINK YOUR APPLICATION IS READY TO SUBMIT? Not without the following UCLA hurdles.
Work with your administrator to complete the internal forms as you assemble your proposal
(before deadline):
Internal Budget in excel for each year of the award
EPASS (updated golden rod) Proposal Summary Form with PI signature
eDGE Financial Conflict of Interest Disclosures (FCOI) requirements are completed online for
Public Health Service agencies. Remind all UCLA Key personnel to login and complete.
PI Exception Letter

15. Rigor and Authentication of Reagents:
https://ctsi.ucla.edu/funding/files/view/docs/RigorandReproducibility_Rochester.pdf
https://grants.nih.gov/grants/guide/notice-files/NOT-OD-16-004.html
https://grants.nih.gov/reproducibility/module_1/presentation.html

16. Case Histories….Lessons
TIMOTHY W. BREDY
Assistant Professor UCI,
Neurobiology and Behavior School of Biological
Sciences Fellow, Center for the Neurobiology of
Learning and Memory Ph.D., McGill
University Phone: (949) 824-3152 Email:
tbredy@uci.edu University of California,
Irvine 102 Bonney Research Laboratory Mail
Code: 3800 Irvine, CA 92697

17. 1: Bredy TW, Barad M. Social modulation of associative fear learning by pheromone communication. Learn Mem.
2008 Dec 30;16(1):12-8. doi:10.1101/lm.1226009. Print 2009 Jan. PubMed PMID: 19117912; PubMed Central
PMCID: PMC2632855.
2: Bredy TW, Barad M. The histone deacetylase inhibitor valproic acid enhances acquisition, extinction, and
reconsolidation of conditioned fear. Learn Mem. 2008Jan 3;15(1):39-45. doi: 10.1101/lm.801108. Print 2008 Jan.
PubMed PMID: 18174372;PubMed Central PMCID: PMC2170514.
3: Bredy TW, Wu H, Crego C, Zellhoefer J, Sun YE, Barad M. Histone modifications around individual BDNF gene
promoters in prefrontal cortex are associated with extinction of conditioned fear. Learn Mem. 2007 Apr
6;14(4):268-76. Print 2007Apr. PubMed PMID: 17522015; PubMed Central PMCID: PMC2216532.
4: Bredy TW, Brown RE, Meaney MJ. Effect of resource availability on biparental care, and offspring neural and
behavioral development in the California mouse (Peromyscus californicus). Eur J Neurosci. 2007 Jan;25(2):567-75.
PubMed PMID:17284199.
5: Bredy TW. Behavioural epigenetics and psychiatric disorders. Med Hypotheses. 2007;68(2):453. Epub 2006 Sep
11. PubMed PMID: 16963190.
6: Zhang TY, Bagot R, Parent C, Nesbitt C, Bredy TW, Caldji C, Fish E, AnismanH, Szyf M, Meaney MJ. Maternal
programming of defensive responses through ustained effects on gene expression. Biol Psychol. 2006 Jul;73(1):72-
89. Epub2006 Feb 28. Review. PubMed PMID: 16513241.
7: Bredy TW, Zhang TY, Grant RJ, Diorio J, Meaney MJ. Peripubertal environmental enrichment reverses the effects
of maternal care on hippocampal development and glutamate receptor subunit expression. Eur J Neurosci. 2004
Sep;20(5):1355-62.PubMed PMID: 15341607.
8: Bredy TW, Lee AW, Meaney MJ, Brown RE. Effect of neonatal handling and paternal care on offspring cognitive
development in the monogamous Californiamouse (Peromyscus californicus). Horm Behav. 2004 Jun;46(1):30-8.
PubMed PMID:15215039.
9: Bredy TW, Grant RJ, Champagne DL, Meaney MJ. Maternal care influences neuronal survival in the hippocampus
of the rat. Eur J Neurosci. 2003Nov;18(10):2903-9. PubMed PMID: 14656341.
10: Bredy TW, Humpartzoomian RA, Cain DP, Meaney MJ. Partial reversal of the effect of maternal care on cognitive
function through environmental enrichment. Neuroscience. 2003;118(2):571-6. PubMed PMID: 12699791.
Good pedigree, most first authored papers, consistent productivity (medium-good impact),
not immediately NIDA obvious, but NIDA interested in learning and memory
processes/plasticity, different labs PhD and postdoc.

18. Kate Wassum Ph. D.,
Associate Professor UCLA
PhD UCLA
Primary : Learning and
Behavior
Secondary: Behavioral
Neuroscience
1: Wassum KM, Ostlund SB, Balleine BW, Maidment NT. Differential dependence o fPavlovian incentive
motivation and instrumental incentive learning processes on dopamine signaling. Learn Mem. 2011 Jun
21;18(7):475-83.
2: Wassum KM, Cely IC, Balleine BW, Maidment NT. Micro-opioid receptor activation in the basolateral
amygdala mediates the learning of increases but not decreases in the incentive value of a food reward. J
Neurosci. 2011 Feb 2;31(5):1591-9.
3: Ostlund SB, Wassum KM, Murphy NP, Balleine BW, Maidment NT. Extracellular dopamine levels in
striatal subregions track shifts in motivation and response cost during instrumental conditioning. J Neurosci.
2011 Jan 5;31(1):200-7.
4: Wassum KM, Cely IC, Maidment NT, Balleine BW. Disruption of endogenous opioid activity during
instrumental learning enhances habit acquisition. Neuroscience.2009 Oct 20;163(3):770-80. doi:
10.1016/j.neuroscience.2009.06.071. Epub 2009 Jul18. PubMed PMID: 19619616; PubMed Central PMCID:
PMC3065789.
5: Wassum KM, Ostlund SB, Maidment NT, Balleine BW. Distinct opioid circuits determine the palatability
and the desirability of rewarding events. Proc NatlAcad Sci U S A. 2009 Jul 28;106(30):12512-7. doi:
10.1073/pnas.0905874106. Epub2009 Jul 13. PubMed PMID: 19597155; PubMed Central PMCID:
PMC2718390.
6: Wassum KM, Evans CJ. International Narcotics Research Conference - 39thAnnual Meeting. IDrugs. 2008
Sep;11(9):646-9. PubMed PMID: 18763214.
7: Wassum KM, Tolosa VM, Wang J, Walker E, Monbouquette HG, Maidment NT. SiliconWafer-Based
Platinum Microelectrode Array Biosensor for Near Real-Time Measurement of Glutamate in Vivo. Sensors
(Basel). 2008;8(8):5023-5036. PubMedPMID: 19543440; PubMed Central PMCID: PMC2699285.
8: Wightman RM, Heien ML, Wassum KM, Sombers LA, Aragona BJ, Khan AS, AriansenJL, Cheer JF, Phillips
PE, Carelli RM. Dopamine release is heterogeneous within microenvironments of the rat nucleus
accumbens. Eur J Neurosci. 2007Oct;26(7):2046-54. Epub 2007 Sep 14. PubMed PMID: 17868375.
9: Cheer JF, Wassum KM, Sombers LA, Heien ML, Ariansen JL, Aragona BJ, Phillips PE, Wightman RM. Phasic
dopamine release evoked by abused substances requires cannabinoid receptor activation. J Neurosci. 2007
Jan 24;27(4):791-5. PubMedPMID: 17251418.
10: Cheer JF, Wassum KM, Wightman RM. Cannabinoid modulation of electrically evoked pH and oxygen
transients in the nucleus accumbens of awake rats. JNeurochem. 2006 May;97(4):1145-54. PubMed PMID:
16686693.
11: Heien ML, Khan AS, Ariansen JL, Cheer JF, Phillips PE, Wassum KM, WightmanRM. Real-time
measurement of dopamine fluctuations after cocaine in the brain of behaving rats. Proc Natl Acad Sci U S A.
2005 Jul 19;102(29):10023-8. Epub 2005Jul 8. PubMed PMID: 16006505; PubMed Central PMCID:
PMC1177422.
12: Cheer JF, Wassum KM, Heien ML, Phillips PE, Wightman RM. Cannabinoids enhance subsecond
dopamine release in the nucleus accumbens of awake rats. J Neurosci.2004 May 5;24(18):4393-400.
PubMed PMID: 15128853.
Good pedigree, many 1st
authored papers, consistent
productivity (high impact),
NIDA-related research. CV
exceptionally strong, many
awards……?????? No K99

19. I got a score 38 on my K99, no percentile. I was planning to resubmit, but then got a job.
From my reading of the statement the training environment was the major issue.
Here is the text from her summary statement that she allowed me to share:
However, enthusiasm is tempered by the fact that the proposal is not really distinguished from the candidate’s previous
work in this environment. The training does not really appear to add to the applicant’s already extensive abilities and
experiences gained in this same environment with the same mentors. Some additional related weaknesses described by
the individual reviewers: Although the application is well-written and sophisticated, especially for an individual just 1
year after earning the PhD, it was unclear how the proposed training plan differed from traditional early stage post-
doctoral studies. Despite demonstrated expertise in addiction related behavioral and neurochemical assessments, the
candidate states her need for further training in neurochemistry in vivo as well as behavioral and pharmacological
techniques. The case for additional training in these disciplines was difficult to discern. Although the principal
investigator has taken advantage of the thriving scientific resources at UCLA during her graduate and postdoctoral
training, the application was unclear how further training in the same environment would achieve the goals of the K99.
For example, the proposed K99 mentor, Dr Maidment, is co-author on all the applicant’s publications from her time at
UCLA, including the predoctoral tenure. Similarly, the predoctoral mentor, Dr Balleine, continues as co-author on papers
described in the application as postdoctoral projects. Notwithstanding the potentially interesting data that might be
generated from the proposed studies, it is unclear whether additional training will be obtained in pharmacology given the
limited scope of drug studies that are proposed and the fact that those studies occur only in the independent phase. A
number of techniques and procedures mentioned in the training plan do not appear to be incorporated into the proposed
research plan. The stated justification for this application is the candidate’s need for additional “training in in vivo
neurochemistry and the behavioral and pharmacological techniques of addiction research” (page 50). As documented by
joint publications by the candidate and the mentor as long ago as 2008, it would appear as though the candidate has
considerable experience with most of the techniques to be used and surely has the behavioral training that is necessary
for the proposed studies. Drug studies will occur in the independent phase so no obvious training in neuropharmacology
will occur under this plan. Do not see that the extra training proposed advances the applicant’s career prospects. The
applicant already has publications/work on methods proposed, i.e. use of Glu biosensors. The applicant also appears to
have extensive behavioral training. Does not seem appropriate for a K99 – the application seems to be continuation of
training rather than seeking really new opportunities. Continuing in same environment – proposed mentor has been an
important part of all her graduate and postdoc work to date and is senior author on many of her publications.

20. Amynah Pradhan PhD
Canadian Citizen
PhD CNRS France,
Postdoc UCLA
Assistant Professor
Department of Psychiatry
University of Illinois
Good Pedigree, most 1st
authored papers, impact is
med (2010 high), NIDA
relevance – pain (opioids) – 6
years out of post-doc
motherhood (rules changed
from 5 to 4 years after
graduation recently).
1: Lutz PE, Pradhan AA, Goeldner C, Kieffer BL. Sequential and opposingalterations of
5-HT(1A) receptor function during withdrawal from chronic morphine. Eur
Neuropsychopharmacol. 2011 Nov;21(11):835-40.
2: Pradhan AA, Walwyn W, Nozaki C, Filliol D, Erbs E, Matifas A, Evans C,Kieffer BL.
Ligand-directed trafficking of the δ-opioid receptor in vivo: two paths toward
analgesic tolerance. J Neurosci. 2010 Dec 8;30(49):16459-68.
3: Pradhan AA, Yu XH, Laird JM. Modality of hyperalgesia tested, not type ofnerve
damage, predicts pharmacological sensitivity in rat models of neuropathic pain. Eur J
Pain. 2010 May;14(5):503-9.
4: Pradhan AA. Botulinum toxin: An emerging therapy in female bladder outlet
obstruction. Indian J Urol. 2009 Jul;25(3):318-20.
6: Pradhan AA, Gogate PR. Degradation of p-nitrophenol using acoustic cavitation and
Fenton chemistry. J Hazard Mater. 2010 Jan 15;173(1-3):517-22.
7: Pradhan AA, Becker JA, Scherrer G, Tryoen-Toth P, Filliol D, Matifas A, Massotte D,
Gavériaux-Ruff C, Kieffer BL. In vivo delta opioid receptor internalization controls
behavioral effects of agonists. PLoS One.2009;4(5):e5425.
8: Pradhan AA, Siau C, Constantin A, Clarke PB. Chronic morphine administration
results in tolerance to delta opioid receptor-mediated antinociception. Neuroscience.
2006 Aug 25;141(2):947-54.
9: Pradhan AA, Clarke PB. Pharmacologically selective block of mu
opioidantinociception by peptide nucleic acid antisense in absence of detectable
exvivo knockdown. Eur J Pharmacol. 2005 Jan 4;506(3):229-36.
10: Pradhan AA, Clarke PB. Comparison between delta-opioid receptor functional
response and autoradiographic labeling in rat brain and spinal cord. J CompNeurol.
2005 Jan 24;481(4):416-26. Pu
11: Pradhan AA, Levine MA. Warfarin use in atrial fibrillation: A random samplesurvey
of family physician beliefs and preferences. Can J Clin Pharmacol. 2002
Winter;9(4):199-202.
12: Pradhan AA, Cumming P, Clarke PB. [125I]Epibatidine-labelled nicotinicreceptors
in the extended striatum and cerebral cortex: lack of association with serotonergic
afferents. Brain Res. 2002 Nov 8;954(2):227-36. PubMed PMID:12414106.

21. Anna Taylor, PhD
PhD Canada
Canadian Citizen
Post-Doc UCLA
Now Assistant Professor
University of Alberta
(forfeited R00)
Good Pedigree, most 1st
authored papers, impact is
med-high, NIDA relevance
– pain (opioids) – 6 years
out of post-doc. Funded 2
years after review.
Weird things happen!
Cahill CM, Walwyn W, Taylor AMW, Pradhan AAA, Evans CJ. (2016). Allostatic mechanisms of opioid tolerance
beyond desensitization and downregulation. Trends Pharmacol Sci 37(11):963-976
Taylor AMW, Mehrabani S, Liu S, Taylor AJ, Cahill CM. (2016) Topography of microglial activation in sensory
and affect related brain regions in chronic pain. J Neurosci Res
Taylor AM, Becker S, Schweinhardt P, Cahill C. (2016) Mesolimbic dopamine signaling in acute and chronic
pain: implications for motivation, analgesia, and addiction. Pain 157(6):1194-8.
Taylor AMW, Castonguay A, Ghogha A, Vayssiere P, Pradhan AAA, Mehrabani S, Xue L, Wu J, Levitt P, De
Koninck Y, Evans CJ, Cahill CM. (2016) Neuroimmune regulation of GABAergic neurons within the ventral
tegmental area during withdrawal from chronic morphine. Neuropsychopharmacology, 41:949-959
Taylor AM, Castonguay A, Taylor, A, Murphy N, Ghogha A, Cook C, Xue L, Olmstead M, De Koninck Y, Evans C,
Cahill C (2015). Microglia disrupt mesolimbic reward circuitry in chronic pain. J Neurosci 35(22):8442-8450
Charrua A, Pinto R, Taylor A, Canelas A, Ribeiro-da-Silva A, Cruz CD, Birder LA, Cruz F (2015) Can the
adrenergic system be implicated in the pathophysiology of bladder pain syndrome/interstitial cystitis? A
clinical and experimental study. Neurourol Urodyn. Epub.
Cahill CM, Taylor AM, Cook C, Ong E, Moron JA, Evans CJ (2014). Does the kappa opioid receptor system
contribute to pain aversion? Front Pharmacol 15;5:253
Taylor AMW, Roberts KW, Pradhan AA, Walwyn W, Lutfy K, Carroll FI, Cahill CM, Evans CJ (2014). Kappa
opioid receptor-mediated analgesia is blocked by a delta opioid receptor agonist. British Journal of
Pharmacology, 172(2):e102334
Taylor AMW, Murphy NP, Evans CJ, Cahill CM (2014) Correlation between ventral striatal catecholamine
content and nociceptive thresholds in neuropathic mice. J Pain 15(8): 878-885.
Taylor, AMW. (2013) Pain and reward: How the affective-motivational system is perturbed in chronic pain.
Postdoctoral Research Journal. Vol 1, No.2.
Taylor, AMW and Ribeiro-da-Silva A. (2012). Consequences of the ablation of non-peptidergic afferents in an
animal model of trigeminal neuropathic pain. Pain. 153: 1311-1319.
Farmer, M.A., Taylor, AMW, Bailey, A.L., McIntyre, L.C., Milagrosa, Z.E., Crissman, H.P., Bennet, G.J., Ribeiro-
da-Silva, A., Binik, T.M., and Mogil, J.S. (2011) Recurrent vulvovaginal candidiasis as an etiology of provoked
vestibulodynia. Science Translational Medicine. 101ra91.
Cahill, C.M. and Taylor, AMW. (2011) A piece of the puzzle is revealed for delta opioid analgesia. Pain. 152
(6): 1217-1218.
Taylor, AMW. and Ribeiro-da-Silva, A. (2011). GDNF levels in the lower lip skin in rat model of trigeminal
neuropathic pain: Implications for non-peptidergic fiber re-innervation and parasympathetic sprouting. Pain.
52 (7): 1502-1510.
Taylor, AMW, Peleshok, J.C., and Ribeiro-da-Silva, A. (2009) Distribution of P2X3-immunoreactive fibers in
hairy and glabrous skin of the rat. J Comp Neurol. (514):555-566.
Riedl, M.S., Schnell, S.A., Overland, A.C., Chabot-Dore, A.J., Taylor, AMW, Ribeiro-da-Silva, A., Elde, R.P.,
Wilcox, G.L., and Stone, L.S. (2009) Coexpression of alpha2a adrenergic and delta opioid receptors in
substance P-Containing terminals in rat dorsal horn. J Comp Neurol. (513) 385-398.
Holdridge, S.C., Armstrong, S.A., Taylor, AMW, and Cahill, C.M. (2007) Behavioral and morphological evidence
for the involvement of glial cell activation of delta opioid receptor function: implications for the development
of opioid tolerance. Mol Pain. 3:7.